
Mindstate Design Labs
Clinical-stage AI neuroengineering platform
- Founded
- 2021
- Status
- Active
- Stage
- Early
- Team size
- 7
- Location
- San Francisco, CA, USA
- Category
- Biotech & Drug Discovery
- Sector
- Drug Discovery and Delivery
About Mindstate Design Labs
We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination emotions in a bottle such as empathy, awe, clarity, or beauty.
Clinical trials
1 registered trial with this company as lead sponsor, 2024.
- Phases
- Phase 1 (1)
- Status
- Completed (1)
- Conditions
- Mental Health Disorders
Source: ClinicalTrials.gov.
Securities filings
1 Form D filing on record, 2024.
Filed as Mindstate Design Labs, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
